What actually happens when you stop taking Ozempic

What's this video probably claiming?

Based on the caption and creator context, this video is almost certainly walking viewers through the well-documented rebound effect after stopping semaglutide. Levity is a GLP-1 focused wellness brand, so the content likely covers weight regain, appetite returning, blood sugar changes, and possibly metabolic slowdown. These are real phenomena, and they deserve accurate framing. The risk here is not outright misinformation, it is incomplete storytelling. A 60-second TikTok can accurately say "weight comes back" while completely omitting why, how fast, whether that applies equally to everyone, and what the clinical literature says about long-term strategies. The framing also matters enormously. Presenting discontinuation effects as scary or dramatic without context can push people toward staying on medication out of fear rather than informed decision-making, which is a clinical and ethical problem.

What does the science actually show?

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) is the definitive reference here. Participants who stopped semaglutide 2.4mg after 68 weeks regained roughly two-thirds of their lost weight within one year of stopping. On average, that meant gaining back about 11.6 of the 17.3 pounds lost. Importantly, cardiometabolic improvements, including blood pressure, blood sugar, and lipid levels, also largely reversed. This is not a fringe finding. It has been replicated in real-world cohorts and matches what we know about obesity as a chronic, relapsing condition requiring ongoing management. The biology is not mysterious: semaglutide suppresses appetite and slows gastric emptying via GLP-1 receptor agonism. When the drug clears the system, those effects disappear. The underlying biology driving weight gain does not change because someone took a drug for a year.

Where does the social media noise diverge from clinical reality?

The noise tends to fall into two camps. The first overstates the rebound, framing it as inevitable total regain and implying the drug was therefore pointless. The second understates it, glossing over discontinuation effects to avoid discouraging new users. Both distort the clinical picture. What the studies actually show is a spectrum: some people retain meaningful weight loss after stopping, particularly those who changed diet and exercise habits during treatment. The SUSTAIN and SCALE trial data suggest that lifestyle modifications made while on the drug can buffer some regain, though they do not eliminate it. TikTok content also rarely addresses that semaglutide is FDA-approved as a chronic treatment, not a short-term intervention. Stopping is not a failure of the drug, it is an off-label or non-indicated use pattern that the clinical trials were not designed around. The framing of "what happens when you stop" can implicitly pathologize discontinuation without acknowledging legitimate clinical reasons someone might stop, including side effects, cost, or medical guidance.

What should you actually know?

Weight regain after stopping GLP-1 medications is real, well-documented, and physiologically expected. That is not a reason to panic or to assume you will return to exactly where you started. The rate of regain matters. The STEP 1 extension showed most regain occurred in the first 20 weeks post-discontinuation, then slowed. If you stop semaglutide, you are not facing a cliff, you are facing a slope, and the gradient depends heavily on what else is in place. Caloric habits, physical activity, sleep, and stress all influence how quickly weight returns. Patients with type 2 diabetes face additional considerations: glycemic control can deteriorate meaningfully after stopping, and that requires active monitoring and coordination with a prescribing clinician. If you are considering stopping a GLP-1 medication for any reason, that conversation belongs with your doctor, not a TikTok comment section. Tapering strategies and transition plans exist and they matter.